The Academy of Managed Care Pharmacy (AMCP) thanks the Office of Management and Budget (OMB) for the opportunity to provide comments in response to the proposed rule titled Regulation for Federal Financial Assistance.
On July 16, 2026, the Centers for Medicare and Medicaid Services released revised draft guidance on how manufacturers must effectuate the Maximum Fair Price (MFP) under the Medicare Price Negotiation Program for Initial Price Applicability Year (IPAY) 2028.
AMCP's Q3 2026 Precision Medicine Bulletin is now available, featuring a recap of key precision medicine developments from 2026, a review of recent clinical guidelines, highlights from new publications in the field, and updates on AMCP's submission to the National Comprehensive Cancer Network (NCCN).
The Academy of Managed Care Pharmacy (AMCP) convened stakeholders across managed care, patient advocacy, life sciences, and research for its Partnership Forum, Insights to Impact: Advancing the Use of Patient Experience Data in Payer Decision-Making, held in Alexandria, Va., in June 2026. The forum focused on how patient experience data (PED) can be more consistently evaluated and applied within payer decision-making frameworks.
In June 2026, AMCP convened stakeholders across managed care, patient advocacy, life sciences, and research in Alexandria, VA, for its Partnership Forum, From Insights to Impact: Advancing the Use of Patient Experience Data (PED) in Payer Decision-Making.
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the CY 2027 Medicare Outpatient Prospective Payment System (OPPS) proposed rule (Proposed Rule).
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and begins when abnormal cells in the lungs grow out of control. Tumors can form in the lung tissue or airways and may spread to other parts of the body if not detected early. Several subtypes of NSCLC exist, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
